Literature DB >> 3261750

Signal transduction of gamma/delta T cell antigen receptor with a novel mitogenic anti-delta antibody.

Y J Wu1, W T Tian, R M Snider, C Rittershaus, P Rogers, L LaManna, S H Ip.   

Abstract

Human T lymphocytes express either alpha/beta- or gamma/delta-TCR in association with the CD3 complex. We have isolated a mAb, delta TCS1, that immunoprecipitated the gamma/delta-TCR heterodimer from cell lysates of Peer and Molt-13 leukemia cell lines. After dissociation of the gamma- and delta-chains of TCR by treatment with SDS, delta TCS1 specifically immunoprecipitated the delta-chain. This antibody bound to the surface of other gamma/delta-positive T cell lines and clones and was able to stimulate the proliferation of a minor cell population (0.9 to 4.0%) of resting human PBL. Upon binding to gamma/delta-TCR-bearing Molt-13 cells and PBL, delta TCS1 elicited a fura-2 Caa+ signal indicating that the gamma/delta-receptor is functionally similar to the alpha/beta-heterodimer. These data indicate that the delta TCS1 antibody recognizes an epitope on TCR delta-chain and its mitogenic activity should be useful in characterizing the functional properties of human gamma/delta-positive T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261750

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Preferential activation of peripheral blood V gamma 9+ gamma/delta T cells by group A, B and C but not group D or F streptococci.

Authors:  A Bender; D Kabelitz
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

2.  Increased numbers of T lymphocytes with gamma delta-positive antigen receptors in a subgroup of individuals with pulmonary sarcoidosis.

Authors:  B Balbi; D R Moller; M Kirby; K J Holroyd; R G Crystal
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

Review 3.  Newly identified gamma delta and beta delta T-cell receptors.

Authors:  F Hochstenbach; M B Brenner
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

4.  Selective gamma-chain T-cell receptor gene rearrangements in a patient with Omenn's syndrome: absence of V-II subgroup (V gamma 9) transcripts.

Authors:  G Mathioudakis; R A Good; Y Chernajovsky; N K Day; C D Platsoucas
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

5.  Differential activation requirements associated with stimulation of T cells via different epitopes of CD3.

Authors:  H Yang; R M Parkhouse
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

6.  Expression of T-cell receptors TcR1 (gamma/delta) and TcR2 (alpha/beta) in the human intestinal mucosa.

Authors:  L K Trejdosiewicz; C J Smart; D J Oakes; P D Howdle; G Malizia; D Campana; A W Boylston
Journal:  Immunology       Date:  1989-09       Impact factor: 7.397

7.  Identification of two distinct subsets of bovine gamma delta T cells with unique cell surface phenotype and tissue distribution.

Authors:  N D Machugh; J K Mburu; M J Carol; C R Wyatt; J A Orden; W C Davis
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

8.  Restriction of the T-cell receptor V delta gene repertoire is due to preferential rearrangement and is independent of antigen selection.

Authors:  N Migone; S Padovan; C Zappador; C Giachino; M Bottaro; G Matullo; C Carbonara; G D Libero; G Casorati
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

9.  Analysis of T cell receptors in rheumatoid arthritis: the increased expression of HLA-DR antigen on circulating gamma delta+ T cells is correlated with disease activity.

Authors:  A Lamour; F Jouen-Beades; O Lees; D Gilbert; X Le Loet; F Tron
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

10.  Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis.

Authors:  R Shimonkevitz; C Colburn; J A Burnham; R S Murray; B L Kotzin
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.